×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

cureTV – Empowering Patients Through Video

Conor Killmurray
While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.
 
Dr. Eric Jonasch
The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.
 
Dr. Ian Flinn
“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Here more about this treatment in his interview with CURE®
 
Dr. Ian Flinn
“I think we’re in a mix of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years,” said Dr. Ian Flinn in an interview with CURE®.
 
Rachel J. Wong, RD, CSO, LD.
One oncology dietitian shares her expertise with patients and survivors of cancer on how to maximize their trip to the grocery store by planning their meals ahead of time.
 
Dr. Ian Flinn
The development of bispecific antibodies and antibody drug conjugates could be exciting advancements for patients with lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.
 
Dr. Ian Flinn
Evidence shows that Bruton’s tyrosine kinase inhibitors, one of many targeted therapies, are highly effective in patients with mantle cell lymphoma.
 
Dr. Ian Flinn
The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.
 
Martha Raymond
Caregivers are an essential part of any patient or survivor’s cancer journey and social distancing due to COVID-19 has made the challenges of caregiving even more difficult. However, one expert details how caregivers can still stay connected during the pandemic.
 
Dr. Scott Irwin
“For the patients that are nervous about how this is going to end, or what's going to happen, I would say that that's true for them outside of the COVID crisis because that's the same question they have about their cancer,” Dr. Scott A. Irwin said.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×